Elevated thrombin, which is linked to worse cancer outcomes, activates PAR-1 receptors on both platelets and cancer cells [124] which promote tumor growth, invasion, and survival [125] as shown with the progression of KRAS mutant CRC via the PAR1-PDK1-AKT signaling pathway [126]. This evidence concerns the gene KRAS and cancer.